How We Collaborate
Dualogics engages in a variety of collaboration structures. These include licensing the OrthoMab technology to enable independent commercialization of OrthoMab products and co-development arrangements which empower partners to optimize candidates jointly with Dualogics.
Are there any targets that are off-limits/already have been exclusively licensed?
No, Dualogics can operate internally or collaboratively in any therapeutic area. We work non-exclusively in regards to target, so there is no target that is off-limits.
Who else is using this technology to develop bispecific antibodies?
The OrthoMab platform was co-developed with Eli Lilly, who are also using this technology to develop innovative therapies.
Why would I choose the OrthoMab platform over any of the other ways to make a bispecific antibody?
While it is true that there are many ways to make a bispecific antibody, not all methods are equal. We set out to make a simple way to generate bispecific antibodies from existing antibody sequences. We don’t require the use of a common light chain, use scFvs, or multiple cell lines. OrthoMab antibodies are highly similar to naturally occurring human antibodies, which means they retain the stability and manufacturability of a standard therapeutic IgG.